drugset / Trial / NCT01411124

Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

NCT01411124

Phase 1 Completed 36 enrolled XenoPort, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a double-blind, placebo-and active-controlled 3-period crossover study designed to assess the effect of GEn 600 mg on simulated driving performance in healthy volunteers.

Timeline

Start
2011-06
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diphenhydramine Unknown 50 mg
Subject gabapentin enacarbil Small molecule 600 mg